title: Differential modulation of gamma-aminobutyric acid receptors by caprolactam derivatives with central nervous system depressant or convulsant activity.
abstract: The effects of a series of caprolactam derivatives with central depressant, convulsant or muscle relaxant activity were investigated upon gamma-aminobutyric acid (GABA) receptor-ionophore binding to rat brain membranes using [3H]GABA, [3H]GABA, [3H]muscimol and [35S]-tert.-butylbicyclophophorothionate ([35S]TBPS) as ligands, and GABA responses in mouse spinal cord neurones in dissociated cell culture. Some caprolactams produced a picrotoxin-like chloride-dependent partial inhibition of muscimol binding and were potent inhibitors of TBPS binding. One compound that was further investigated (4,4,6,6-tetramethylhexahydro-2H-azepin-2-one), inhibited GABA responses and increased the frequency of paroxysmal depolarizations in cultured neurones. Other caprolactams enhanced muscimol binding and were relatively weak inhibitors of TBPS binding, and one (3,3-diallyl-6,6-dimethylhexahydro-2H-azepin-2,4-dione) was shown to enhance GABA responses and produced quiescence of activity in cultured neurones. There was a direct correlation between caprolactam effects on muscimol binding in the presence of chloride ions and their effects on TBPS binding suggesting a similar site of action for the caprolactams influencing the binding of these two ligands. For the two classes of caprolactams, with respect to inhibition or enhancement of muscimol binding, there appeared to be a relationship between in vitro effects and their convulsant or depressant activity in mice. Caprolactams may be useful low molecular weight probes for the study of GABA receptor-ionophore complexes.
authors.forename: J H
authors.initials: JH
authors.lastname: Skerritt
authors.forename: G A
authors.initials: GA
authors.lastname: Johnston
authors.forename: S C
authors.initials: SC
authors.lastname: Chow
authors.forename: R L
authors.initials: RL
authors.lastname: MacDonald
authors.forename: R H
authors.initials: RH
authors.lastname: Prager
authors.forename: A D
authors.initials: AD
authors.lastname: Ward
mesh_terms: D000818:Animals; D001381:Azepines / Q000494:pharmacology*; D002209:Caprolactam / Q000031:analogs & derivatives / Q000494:pharmacology*; D002490:Central Nervous System / Q000187:drug effects*; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D003292:Convulsants / Q000494:pharmacology*; D008297:Male; D009125:Muscle Relaxants, Central / Q000494:pharmacology*; D010424:Pentobarbital / Q000494:pharmacology; D010852:Picrotoxin / Q000031:analogs & derivatives / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011963:Receptors, GABA-A / Q000187:drug effects*; D054830:Sesterterpenes; D013329:Structure-Activity Relationship
chemical_list: D001381:Azepines; D002209:Caprolactam; D002492:Central Nervous System Depressants; D003292:Convulsants; D009125:Muscle Relaxants, Central; D010424:Pentobarbital; D010852:Picrotoxin; D011963:Receptors, GABA-A; D054830:Sesterterpenes; C022961:picrotoxinin